EMAIL THIS PAGE TO A FRIEND

Journal of cellular physiology

LB-1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIF-1α and Stat3 Signaling.


PMID 25655308

Abstract

Hypoxia is widely present in pancreatic cancer and subsequently causes the overexpression of hypoxia-inducible factor-1α (HIF-1α) and signal transducer and activator of transcription-3 (Stat3). HIF-1α and Stat3 function cooperatively to regulate a number of downstream genes that are implicated in tumorigenesis. Thus, inhibition of HIF-1α and Stat3 is a potential therapeutic strategy for pancreatic cancer. In this study, we explored how LB-1, a novel triptolide (LA) derivative, exerted its antitumor effect through blockade of HIF-1α and Stat3 signaling. Our data showed that LB-1 was able to inhibit the proliferation and colony formation of Mia-PaCa2 and SW1990 cells. LB-1 suppressed HIF-1α protein accumulation by promoting its proteasome degradation and reducing transactivation. Moreover, the silence of HIF-1α by shRNA partially prevented the proliferation inhibition triggered by LB-1. As expected, LB-1 also decreased Stat3 protein accumulation and blocked the physical interactions between HIF-1α/p300/phosphor-Stat3 (p-Stat3) at the pharmacological concentration to reduce VEGF expression, thereby hypoxia-induced angiogenesis. In the Mia-PaCa2 nude xenograft model, therapeutic treatment with LB-1 significantly inhibited tumor growth and had minimal systemic toxicity compared to the mother drug LA. Furthermore, in accordance with in vitro results, HIF-1α activation and Stat3 expression in tumors were blocked by LB-1 through mTOR-dependent pathway. Taken together, these results illustrate that, as a potent inhibitor of HIF-1α and Stat3 signaling, LB-1 exhibits antitumor effect and could be potentially used to treat pancreatic cancer.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA003128
Anti-EP300 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA004112
Anti-EP300 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4503485
Anti-p300, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4503847
Anti-phospho-4E-BP1 (pSer64) antibody produced in rabbit, affinity isolated antibody
SAB4504328
Anti-phospho-4E-BP1 (pThr36) antibody produced in rabbit, affinity isolated antibody
SAB4504329
Anti-phospho-4E-BP1 (pThr45) antibody produced in rabbit, affinity isolated antibody
SAB4503848
Anti-phospho-4E-BP1 (pThr69) antibody produced in rabbit, affinity isolated antibody
SAB4504686
Anti-phospho-4E-BP1 (pThr70) antibody produced in rabbit, affinity isolated antibody
SAB4300179
Anti-phospho-EIF4EBP1 (pThr45) antibody produced in rabbit, affinity isolated antibody
SAB4300214
Anti-phospho-RPS6KB1 (pSer411) antibody produced in rabbit, affinity isolated antibody
SAB4300225
Anti-phospho-RPS6KB1 (pSer424) antibody produced in rabbit, affinity isolated antibody
SAB4300202
Anti-phospho-RPS6KB1 (pThr421) antibody produced in rabbit, affinity isolated antibody
WH0002033M2
Monoclonal Anti-EP300 antibody produced in mouse, clone 1D2, purified immunoglobulin, buffered aqueous solution
SAB1400094
Monoclonal Anti-EP300 antibody produced in mouse, clone 1B1, purified immunoglobulin, buffered aqueous solution
SAB1403776
Monoclonal Anti-EP300 antibody produced in mouse, clone 1D2, ascites fluid
PLA0096
Rabbit anti-p300 Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.